Gesamtlänge aller Episoden: 3 days 2 hours 4 minutes
Donna LaLonde, Kristian Lum, and Leslie McClure discuss the ASA Task Force on Sexual Harassment and Assault.
Rakhi Kilaru and Olgica Klindworth discuss risk-based monitoring and quality tolerance limits.
Inna Perevozskaya and Bo Huang discuss the changing landscape in oncology clinical development.
Alex Dmitrienko and Kyle Wathen talk about the development of software for biopharmaceutical applications, the new working group and LinkedIn group, and talk a little bit about the new YouTube Channel for the Biopharmaceutical Section.
Zoran Antonijevic, Robert Beckman, Scott Berry & Richard Simon discuss the current application and future of platform trials.
Qi talks about the benefits and challenges of applying deep learning methodologies to electronic medical records.
Richard discusses the importance of the Biopharmaceutical Section and describes what he hopes to accomplish as Chair in 2019.
Toshimitsu Hamasaki describes his work at a major research hospital and discusses the regulatory environment in Japan.
Hong Liu-Seifert and Steve Wilson discuss the challenges of developing new treatments for Alzheimer's Disease and the formation of the scientific working group.
Pam McGovern, Willis Jensen, John Kolassa, and Fanni Natanegara talk about collaboration and the Statistical Partnerships Among Academe, Industry & Government Committee, otherwise known as SPAIG.